The PulseCalendarExplorerLongevity Clinics MapLongevity Investors MapWearables & Nearables MapAbout

Back to Longevity News

Longevity News

Traded: Venture Capital 🦄 on Instagram: "Houdini Bio has emerged from stealth with $1.95 million in pre-seed funding led by SCVC, with participation from Deep Science Ventures and Cambridge Enterprise Ventures, to develop a DNA engineering platform designed to improve the durability and effectiveness of gene therapies. Founded in 2025, the British biotech startup combines machine learning with research into cellular DNA silencing mechanisms to help therapeutic genes evade biological defenses that can reduce treatment efficacy. The company says its platform can increase gene expression by more than tenfold compared to existing approaches, with potential applications across conditions including cystic fibrosis, haemophilia, cancer, dementia, and inherited blindness. FOUNDERS: Jonathan Cohen-Gold & Lee Dunham INVESTORS: SCVC, Deep Science Ventures & Cambridge Enterprise Ventures ROUND: Pre-Seed AMOUNT: $1,950,000 HQ: Cambridge, United Kingdom #VentureCapital #HoudiniBio #JonathanCohenGold #SCVC #DeepScienceVentures TradedVC"

Source: traderVC • Published: 19 Jun 2026, 19:12

Traded: Venture Capital 🦄 on Instagram: "Houdini Bio has emerged from stealth with $1.95 million in pre-seed funding led by SCVC, with participation from Deep Science Ventures and Cambridge Enterprise Ventures, to develop a DNA engineering platform designed to improve the durability and effectiveness of gene therapies. Founded in 2025, the British biotech startup combines machine learning with research into cellular DNA silencing mechanisms to help therapeutic genes evade biological defenses that can reduce treatment efficacy. The company says its platform can increase gene expression by more than tenfold compared to existing approaches, with potential applications across conditions including cystic fibrosis, haemophilia, cancer, dementia, and inherited blindness. FOUNDERS: Jonathan Cohen-Gold & Lee Dunham INVESTORS: SCVC, Deep Science Ventures & Cambridge Enterprise Ventures ROUND: Pre-Seed AMOUNT: $1,950,000 HQ: Cambridge, United Kingdom #VentureCapital #HoudiniBio #JonathanCohenGold #SCVC #DeepScienceVentures TradedVC"

Startup profile focusing on founders, financing and scientific strategy behind a biotech's debut, offering context for investors and scientific readers.

Key Takeaways
  • Houdini Bio is developing a DNA-engineering platform combining machine learning with DNA-silencing research
  • Company reports the platform increases gene expression more than tenfold versus current approaches
  • Houdini Bio secured $1.95 million pre-seed funding to pursue therapies for cystic fibrosis
Read Original Source